Shigeru Yutani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/625198/publications.pdf

Version: 2024-02-01

1.1	220	1307594	1372567
11	230	/	10
papers	citations	h-index	g-index
11	11	11	250
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer. Cancer Immunology Research, 2014, 2, 1154-1162.	3.4	49
2	Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Experimental and Therapeutic Medicine, 2012, 3, 463-469.	1.8	47
3	Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biology and Therapy, 2010, 10, 1266-1279.	3.4	46
4	A randomized phase <scp>II</scp> trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Science, 2017, 108, 838-845.	3.9	30
5	Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncology Reports, 2011, 25, 57-62.	2.6	18
6	Personalized peptide vaccination as secondâ€line treatment for metastatic upper tract urothelial carcinoma. Cancer Science, 2017, 108, 2430-2437.	3.9	14
7	Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers. Cancer Science, 2018, 109, 2660-2669.	3.9	10
8	Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Science, 2017, 108, 1732-1738.	3.9	7
9	Immunological evaluation of peptide vaccination for cancer patients with the <scp>HLA</scp> â€A11 ⁺ or â€A33 ⁺ allele. Cancer Science, 2017, 108, 598-603.	3.9	6
10	Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients. International Journal of Oncology, 2020, 56, 1479-1489.	3.3	2
11	Immune responses of patients without cancer recurrence after a cancer vaccine over a long term. Molecular and Clinical Oncology, 2022, 16, .	1.0	1